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Background: The prevalence of childhood obesity and insulin resistance is rising, increasing the risk of diabetes
mellitus type 2. To prevent these complications, lifestyle intervention is the corner stone in treatment. However,
long-term efficacy of lifestyle intervention is questionable. In addition to lifestyle intervention, pharmacological
treatments have been explored. Metformin has been shown to be moderately effective to reduce BMI in obese
adolescents with hyperinsulinemia. However, data on pharmacokinetics and long-term efficacy and safety are
lacking as well as an evidence-based dosing regimen for this age group. The primary objective of the METFORMIN
study is to determine the effect of adding metformin treatment to lifestyle intervention in reducing BMI in obese
adolescents with insulin resistance. In addition, the pharmacokinetics of metformin in obese adolescents will be studied.
Methods/design: The METFORMIN study is a multi-centre prospective study that consists of two 18-month phases: a
double-blind randomized placebo-controlled trial (part 1) and an open-label follow-up study (part 2). During part 1, the
participants will be given metformin 1,000 mg or placebo twice daily and will be offered a lifestyle intervention
programme; 144 participants will be included, 72 in each arm. Primary endpoints are reduction in body mass index,
insulin resistance, and percentage body fat.
Discussion: This study will provide data on short- and long-term efficacy and safety of metformin and on the
pharmacokinetics of metformin in obese adolescents.
Trial registration: ClinicalTrials.gov number NCT01487993; EudraCT nr. 2010-023980-17. Registration date: 06-01-2011
Keywords: Efficacy, Insulin resistance, Metformin, Paediatric obesity, Pharmacokinetics, SafetyBackground
The prevalence of obesity in adolescents is increasing
rapidly, having a significant impact on both physical and
psychosocial health [1]. Currently, the worldwide pre-
valence of obesity in children and adolescents is 2% to
3%, using the International Obesity Taskforce standard
definition for paediatric obesity in children and adoles-
cents 5 to 17 years of age [2]. In the Netherlands, the* Correspondence: m.elst@antoniusziekenhuis.nl
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article, unless otherwise stated.prevalence of obesity in children and adolescents (4–15
years) of Dutch descent is 1.8% in boys and 2.2% in girls.
In Turkish boys and girls, these numbers are higher,
8.4% and 8.0%, respectively [3].
In obese children and adolescents, insulin resistance,
impaired fasting glucose, impaired glucose tolerance, dys-
lipidaemia, and hypertension occur with increased fre-
quency [4-6]. In addition, several medical conditions, such
as poor pulmonary function, hepatic steatosis, sleep ap-
noea, and orthopaedic complications, are associated with
obesity [1,5,7,8]. These medical conditions often persist
into adulthood and will result in substantial psychosocial
and somatic morbidity, with loss of school or working
days [9].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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surgical interventions [10-12]. Behavioural lifestyle inter-
vention can produce significant reduction of obesity in
children and adolescents [13]. However, the efficacy of
lifestyle intervention programs on body mass index (BMI)
and all related complications on the long-term are ques-
tionable, taking into account the high drop out and the fre-
quent relapse of obesity in this group of patients. Therefore,
in clinical practice, adding a pharmacological agent to con-
ventional treatment is often considered. Three agents have
been studied: orlistat, a gastrointestinal lipase inhibitor,
sibutramine, a serotonin and noradrenalin re-uptake inhibi-
tor, and metformin, an insulin sensitizing agent [10-12,14].
Both orlistat and sibutramine have been shown to have
an additional reducing effect on the absolute BMI in
children and adolescents, yet medication-related adverse
effects, such as tachycardia, hypertension, arrhythmia, and
gastro-intestinal tract symptoms, were frequently reported
[11,15,16]. Efficacy of metformin was investigated in hyper-
insulinemic, obese adolescents by Park et al. in a systematic
review [12]; they concluded that metformin is moderately
efficacious in reducing BMI and insulin resistance in the
short term (less than 6 months). The authors stated that
large long-term studies are needed to establish the role of
metformin in the treatment of obese adolescents. This con-
clusion is based on studies in obese adults without Type 2
diabetes mellitus (T2DM), in which metformin has been
shown to prevent progression from impaired fasting
glucose and impaired glucose tolerance to T2DM [17,18].
Although results in obese children and adolescents are
sparse, these results, and the observed benefits in adults,
have led to increased off-label use of metformin in obese
children and adolescents with, and even without insulin
resistance [19-26].
In conclusion, obesity in adolescence is increasing
rapidly, with large medical and psychosocial sequelae.
While standard treatment is lifestyle intervention, met-
formin is often added to this treatment, despite the lack
of proper randomised trials on efficacy and safety, par-
ticularly upon prolonged treatment [12,27-31]. While
metformin is licensed in adolescents for the treatment
of T2DM, it is not yet licensed for obese children with
and without insulin resistance.
Methods/design
Objectives
This study has four main objectives:
The primary objective of the METFORMIN study is to
determine the efficacy of metformin in combination with
lifestyle intervention in obese adolescents with insulin
resistance versus placebo with lifestyle intervention after
18 months in reducing BMI and insulin resistance. The
secondary objective is to determine the safety and toler-
ability of metformin in obese adolescents with insulinresistance. The tertiary objective is to study the popula-
tion pharmacokinetics (PK) of metformin in obese ado-
lescents. Finally, the quaternary objective is to determine
the long-term (36 months) efficacy and long-term safety
and tolerability of metformin in obese adolescents with
insulin resistance.
Other objectives are to compare values of body fat
measured using bio-impedance with values of body fat
measured using dual energy X-ray absorptiometry (DEXA
scan), and to compare insulin sensitivity measured by the
Whole Body Insulin Sensitivity Index with insulin sensi-
tivity calculated by Homeostasis Model Assessment for
Insulin Resistance (HOMA-IR) in obese children and
adolescents. Furthermore, arterial stiffness will be mea-
sured and evaluated over time.
Design
The metformin study is a multicentre study, divided in
two parts, both of 18 months. The first part is a random-
ized, double-blind placebo controlled trial, with two par-
allel groups. At study entry, participants are randomized
to metformin or placebo for 18 months. All participants
will be offered a lifestyle intervention program. This pro-
gram consists of supervised physical training twice weekly,
and individual dietary advice during hospital visits. Partici-
pants will visit the hospital 9 times during this part of
the study. Between these visits, monthly telephone calls
are made.
The second part of the study is an open label, follow-up
study. Participants who remain obese and insulin-resistant
at entrance of the second part, can choose between met-
formin treatment and no medication. Participants who do
not meet these criteria, do not use medication in this part
of the study. Therefore, after the follow-up study there are
four arms: participants with metformin in both parts, met-
formin in part 1 and no medication in part 2, placebo in
part 1 and metformin in part 2, and placebo in part 1 and
no medication in part 2 (Figure 1).
During part 2, no supervised physical training is of-
fered. Participants using Metformin will visit the hospital
six times, participants not using medication will have
three hospital visits and three phone calls. Participants
using Metformin are seen more frequently to monitor
potential adverse events.
The study protocol has been approved by the Med-
ical Ethical Committee of the St Antonius Hospital,
Nieuwegein, the Netherlands. The study is registered
in the Clinical Trials register (ClinicalTrials.gov number
NCT01487993).
Participants
Recruitment of participants takes place at the paediatric
outpatient clinics of the study centres. Patients are eligible
for this study if they meet the inclusion and exclusion
Figure 1 METFORMIN study flowchart.
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tained from all participants/parents or caretakers.
Sample size
A power analysis for reduction in BMI (primary end-
point) and for reduction of insulin resistance calculatedTable 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age: 10–16 years Presence of T2DM, po
Obesity defined as BMI standard deviation score >2.3 Height <−1.3 SD of
Insulin resistance defined as HOMA-IR ≥3.4 Syndromal disorders
Caucasian descent Pregnancy
Informed consent signed by parents and participant Use of anti-hypergly
(History of) alcohol a
Impaired renal or he
(GFR) <80 ml/min; G
alanine aminotransfe
Insufficient knowledby the HOMA-IR has been performed. For BMI, a sample
size of 47 participants per group (metformin and placebo)
is sufficient to detect a change in BMI of 2.94% with 90%
power. Sample size for HOMA-IR was calculated using
a simulation based on retrospective data available from
our obesity out-patient clinic. Group sample sizes of 60lycystic ovarian syndrome, or endocrine disorders treated with corticosteroids
target height
with or without mental retardation
caemic drugs, ritonavir or ACE-inhibitors
buse
patic function (renal function defined as glomerular filtration rate
FR = 40 × length (cm)/serum creatinine (μmol/l); hepatic function:
rase >150% of normal value for age)
ge of Dutch language
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tection of a difference of 1.6 with a significance level of
0.05. To prevent inadequate power due to drop out of
participants, 20% more patients will be included. This
means a total amount of 144 children and adolescents
have to be included in the study.
Randomisation
Subjects will be assigned to metformin or placebo in ac-
cordance with a randomisation schedule generated by
the department of Clinical Pharmacy of the St Antonius
Hospital, using PASW Statistics 18.0. Randomisation will
be done in blocks of 20 subjects assuring a balanced study
after each 20 consecutive inclusions per research site. All
research staff is blinded for treatment allocation during
the time of the study. Randomisation lists will be kept
under secured access in the clinical pharmacy department
of both participating hospitals.
The research physician assigns included participants
to consecutive study numbers, which correlate with the
randomisation and medication number.
Breaking of the study blind
The study blind will be broken after all participants have
finished part 1 of the study. In case of emergencies (serious
adverse events, suspected unexpected serious adverse
reactions), the blind will be broken after consultation of
the principal investigator. Subsequently, these events
will be reported to the Medical Ethical Committee.
Intervention
Metformin
After randomisation, all participants will receive either
metformin 500 mg tablets or identical placebo tablets.
Medication is given according to an increasing dosage
regimen. In week 1, participants take 1 tablet daily. Every
week, dosage increases with 1 tablet, reaching a max-
imum of 4 tablets in week 4. This maximum dose will
be administered till the end of part 1.
In case the participant develops gastro-intestinal symp-
toms, dosage will be reduced to the last well-tolerated
dosage. Participants will be asked to return remaining
study medication every visit. Pill counts will be performed
by a research assistant.
During the follow-up study, metformin will be admin-
istered according to the dosage regimen of part 1.
Physical training
During part 1 of the study, physical training will be offered
in groups, supervised by a physiotherapist. Training
sessions will be twice weekly, and last for one hour.
The main goals are creating pleasure in physical exer-
cise, improvement of endurance and coordination. At-
tendance at the training will be recorded.All participants will perform a standardised fitness test
at study entry, halfway part 1 and at the end of parts 1
and 2.Statistical analysis
Data will be analysed using IBM SPSS Statistics. Baseline
data will be reported as descriptive statistics. Normally
distributed data will be reported as mean ± SD and non-
parametric data as median (range).Efficacy of metformin
To assess the effect of metformin versus placebo, the
Students T test will be used to compare means of nor-
mally distributed data and the Mann-Whitney U test to
compare nonparametric data. The χ2 test will be used
for dichotomous outcomes (the development of impaired
fasted glucose, impaired glucose tolerance, T2DM, and
the presence of micro- and macro- vascular complications
versus the study groups).
General linear models (analysis of repeated measures)
or mixed models (if too much data is missing) will be
used to determine the therapeutic effect of the drug.
After part 2 of the study, comparisons will be made be-
tween the four subgroups (metformin in part 1 and part 2;
metformin in part 1 and no medication in part 2; placebo
in part 1 and metformin in part 2; placebo in part 1 and
no medication in part 2) (Figure 1).Safety and tolerability
Safety will be reported as the amount of cases in which
hepatic and renal functions exceed safety limits. Toler-
ability will be reported as descriptive statistics of adverse
effects in relation with the achieved dosage level.Pharmacokinetics
All observed metformin plasma concentrations will be
analysed using nonlinear mixed effects modelling to de-
velop a population pharmacokinetics/pharmacodynamics
(PK/PD) model. Using this modelling approach, infre-
quently obtained samples and observations in the clin-
ical situation can be utilized to analyse determinants of
variability in drug response [32-34]. In both the popula-
tion PK (drug concentrations) and PD (efficacy and safety
endpoints) models, the influence of age, bodyweight, BMI,
percentage of body fat, gender, Tanner stage, and genetic
constitution will be evaluated resulting in individualized
dosing regimens. In addition to demographic parameters,
the influence of genetic variation in the SLC47A1 gene,
which may play an important role in the pharmacokinetics
of metformin, is studied [35-37]. If other relevant genes
are discovered during the metformin study, these genes
will also be determined.
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Table 2 shows which measurements are performed during
parts 1 and 2 of the study. In Table 3, blood sampling per
visit is specified. Participants in both the metformin and
placebo group undergo the same procedures and measure-
ments. Two additional measurements, namely indirect
calorimetry, a DEXA scan, and an additional physical
test, are performed in study participants included at the
Jeroen Bosch hospital study site.
Adverse events and co-medication
During scheduled phone calls and hospital visits, partici-
pants and/or their parents will be asked about adverse
events (AEs) and use of co-medication during the past
week(s). Collected data for AEs are: start date, stop date,
description of AE, kind of action taken regarding study
medication (continued, dose adjusted or interrupted, per-
manently discontinued), therapy for AE, severity of AE
(mild, moderate, severe, life threatening, death), whether
the AE was expected, whether the AE was serious, and
whether the AE occurred during study treatment. Col-
lected data for concomitant medication are: start date,
stop date, type, and dose of medication, and duration of
use (single dose, intermittent dosage, chronic use). For
chronically used medication, changes in prescription, i.e.,
dose and frequency, will be checked.
History
At the first visit, an extensive history will be taken. Dur-
ation of pregnancy, birth weight, neonatal feeding, and
the presence of diabetes gravidarum during pregnancy of
the participants is questioned. Further, information on
diseases, hospital admissions, and use of medication,
alcohol, and tobacco is collected. Regarding family history,
data on hypertension, obesity, hypercholesterolemia, car-
diovascular disease (myocardial infarction, stroke, transient
ischemic attack, peripheral arterial occlusions), and dia-
betes mellitus in first (parents) and second degree (grand-
parents, brothers, sisters) family members are collected.
Level of education of participants and both parents is re-
corded, as well as height and weight of both parents. Girls
will be asked whether and when they had their menarche.
Physical examination and anthropometrics
Every visit, except at week 3 and 5, anthropometric mea-
surements are performed. These include: height, weight,
and waist, hip, neck, and right wrist circumference.
Height will be measured with a digital stadiometer in
the St Antonius Hospital, and with an analogue stadi-
ometer at the Jeroen Bosch hospital. Height will be re-
corded to the nearest 0.1 cm.
Weight is recorded on a digital scale in all study centres,
and is recorded to the nearest 0.05 kg. Waist, hip, neck,
and right wrist circumferences are measured with thesame tape-measure in both centres, by the research
physician. All measurements are recorded to the nearest
0.1 cm. Waist circumference is measured at the level of
the navel and hip circumference at the level of the anterior
superior iliac spine. Neck circumference is measured three
times, the smallest circumference is recorded. Circumfer-
ence of the right wrist is measured at the level of Lister’s
tubercle.
Blood pressure and heart rate are measured with sub-
jects in a seated position using a cuff appropriate for the
participants’ arm circumference. In both study centres,
blood pressure will be measured electronically.
During the visits in weeks 0, 37, 73, and 146, an ex-
tended physical examination is performed by the research
physician. This examination includes auscultation of heart,
lungs, and abdomen, and abdomen palpation. Abnormal
findings will be recorded. The skin will be examined for
the presence of acanthosis nigricans, striae, acne, and, in
girls, hirsutism. For all participants, pubertal stage accord-
ing to the classification of Tanner will be recorded. In
girls, this includes development of the breasts and pubic
hair; in boys, stage of pubic hair and testicular volume is
estimated.Blood sampling
Blood samples will be collected by venapuncture or, in
case of an OGTT, by venous cannula during scheduled
hospital visits (Table 2). Before venapuncture or insertion of
the venous cannula, local anaesthetics will be applied to the
skin (Xylocaine spray, 100 mg/mL, AstraZeneca bv). The
specification of measurements per blood sample is shown
in Table 3. All samples will be collected by research staff
and analyzed in the clinical laboratory of the St Antonius
Hospital.Urine sampling
Urine samples will be collected at three time points. The
sample will be analysed for the concentration of creatinine
and micro-albumin, and tested for protein. Additionally,
in the first urine sample of female participants, a preg-
nancy test is performed.Oral glucose tolerance test
Oral glucose tolerance tests (OGTT) will be performed at
four time points. Participants will come to the hospital
after an overnight fast. After insertion of a venous cannula
and after obtaining the baseline blood sample (t = 0), par-
ticipants will receive a solution of glucose: 1.75 g/kg body
weight with a maximum of 75 g, dissolved in 200 to
300 mL of water. Blood samples will be taken for glucose
and insulin concentrations at 30, 60, 90, and 120 minutes
after ingestion of the glucose solution.














PWV Fitness test IWQOL
questionnaire
Dietary diary Calorimetryc DEXA scanc
Part 1
0 x xd x x x x x x x x x x
1a x x
3 x x x
5 x x x
9a x x
13 x x x x
17a x x
21a x x
25 x x x x
29a x x
33a x x
37 x x xd x x x x x x x x
41a x x
45a x x
49 x x x x
53a x x
57a x x
61 x x x x
65a x x
69a x x
73 x x xd x x x x x x x x x x
Part 2
86b x x
98 x x x x
110b x x
122 x x x x
134b x x
146 x x x x x x x x x x x x


















Table 3 Specification of measurements per blood sample
Visit Measurements
Fasted glucose Fasted insulin OGTT (Glucose and insulin at
t = 0, 30, 60, 90 and 120’)
HbA1c Blood count, indices Urea, creatinine ALAT Lipid profile Vitamin B12 CRP DNA Metformin DNA
Part 1
0 x x x x x x x x x x x
3 x
5 x
13 x x x x x
25 x x x x x x x x
37 x x x x*
49 x x x x x x x x
61 x x x x
73 x x x x x x x x x
Part 2
98 x x x x x x x
122 x x x x x x x
146 x x x x x x x x
ALAT, Alanine aminotransferase; CRP, C-reactive protein; HbA1c, Glycated haemoglobin; OGTT, Oral glucose tolerance test.
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During the OGTT of week 37, a metformin day-curve
will be performed. A baseline sample is collected after in-
sertion of the venous cannula (t = 0). Participants will take
the oral study medication after ingestion of the glucose
solution for the OGTT. Afterwards, samples for serum
concentration of metformin are taken at 60, 120, 240,
360, and 480 minutes. Samples will be stored in the toxi-
cological laboratory of the St Antonius Hospital at −20°C
until analysis is to be performed.
Body composition
In order to obtain data on body composition, bio-
impedance analysis is performed at regular time-points.
In all participating hospitals the same leg-to-leg bio-
impedance analysis measurement will be performed
using a Tanita BC-420MA body composition analyser
(Tanita Corporation, Tokyo, Japan). Participants will
stand barefoot on the metal plates of the scale. A cor-
rection for weight of clothes (1 kg), sex, age, and height
are entered manually into the Tanita system. After ana-
lysis, a print out with body weight, estimated percentage
of body fat, fat free mass, and total body water is made.
In study participants of the Jeroen Bosch Hospital, a
DEXA scan will be performed additionally. The DEXA
scan will show the fat distribution and will give the
amount of lean and total body mass.
Arterial stiffness
Arterial stiffness is assessed by pulse wave velocity and
augmentation index. The pulse wave velocity measure-
ment is a non-invasive measurement using ultrasound
and is measured using the SphygmoCor (Model SCOR-Px,
Software version, 7.01; AtCor Medical Pvt. Ltd, Sydney,
Australia). Both pulse wave velocity, which correlates with
stiffness of the aorta, and augmentation index, reflecting
endothelial function, will be used to monitor the develop-
ment of vascular complications. The measurements will be
performed with participants in a supine position. Before
and after the measurement, blood pressure will be re-
corded. All pulse wave velocity measurements will be per-
formed twice. The augmentation index will be calculated
in a pulse wave analysis measurement from the right radial
artery. For calculation of the pulse wave velocity, the dis-
tance between the sternal notch and the expected site for
recording at the right carotid artery and right femoral
artery will be measured with a tape measure to the nearest
0.1 cm. This distance is entered into the computer before
measurements are performed.
Fitness test
Physical fitness of the participants will be monitored using
the modified Shuttle walking test for endurance, while static
and dynamic balance tests, according to Movement-ABCwill be used to test coordination and strength. All tests will
be performed by trained physiotherapists.
Quality of life
Body weight-related quality of life is measured using the
Impact of Weight on Quality of Life-Kids (IWQOL-Kids)
questionnaire [38]. This questionnaire consists of 27 items
in four domains: physical comfort, body esteem, social life,
and family relations; a validated Dutch translation is used
[39]. The questionnaire will be handed out during the
OGTT, or sent to the participants’ home address to be
filled in advance. Participants are free to choose whether
they answer the questionnaire in the hospital or at home.
Diet
Participants will be asked to complete a 3-day dietary
diary three times during part 1 of the study, and once
during the second part of the study. During the following
visit, the diary will be discussed with participants. Advice
on a healthy diet is given by the research physician based
on this diary. If diet advice is not sufficient a dietician will
be consulted.
Measurements performed in a subsample
Indirect calorimetry
This additional test will be performed in one of the par-
ticipating study centres (Jeroen Bosch Hospital). All of
the metabolic processes that occur in the body result
ultimately in the production of heat. Direct calorimetry
measures the heat production directly; indirect calor-
imetry makes use of the assumption that all energy-
releasing reactions in the body ultimately depend on the
utilization of oxygen. Indirect calorimetry, using the venti-
lated hood principle, is a measurement in which the sub-
ject has to lay down in a thermoneutral environment after
an overnight fast. In a time span of 15 min, the subject
needs to lay still while oxygen uptake and dioxide pro-
duction of the body are measured. This measurement is
an estimate of basal metabolic rate. Calorimetry will be
performed when the subject is in fastened condition.
DEXA scan
In participants included at the Jeroen Bosch hospital, an
additional DEXA scan will be performed. This scan will
show fat distribution and will accurately determine lean
and total body mass.
VO2-max test
Maximal oxygen uptake will be measured using a standard-
ized test for maximal aerobic power: the VO2 max test.
The VO2 max test is a single continuous 3- to 5-minute
submaximal effort test on a stationary bicycle. It consists of
progressive increments in effort (graded exercise) to the
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exercise.
Outcome measures
Along with the multiple objectives in this study, there
are multiple outcome measures.
Primary endpoints and measures
Primary study endpoint for efficacy of metformin is the
reduction in BMI standard deviation score, which is
calculated from the anthropometric measurements,
and the reduction of insulin resistance calculated by
the HOMA-IR.
Secondary outcome measures
Secondary outcome parameters for safety of metformin
treatment are hepatic and renal function tests, and con-
centration of vitamin B12. For tolerability, the number
of adverse events (in relation to the achieved dose level)
is the outcome parameter.
Tertiary outcome measures
Tertiary outcome parameters are the PK parameters
of metformin in obese children and adolescents. These
parameters are estimated using population PK-PD model-
ling techniques in which a comprehensive covariate ana-
lysis will be performed allowing to account for variability
in PK parameters on the basis of individual characteristics
such as age, bodyweight, BMI, percentage of body fat,
gender, Tanner stage, and genetic constitution.
Quaternary outcome measures
Quaternary outcome parameters for long-term efficacy
and long-term safety and tolerability (36 months) of met-
formin are similar to the primary and secondary outcome
measures. In addition, the percentage of patients that has
developed impaired fasting glucose, impaired glucose
tolerance, and T2DM is evaluated. Furthermore, the
development of micro- and macro-vascular complica-
tions is assessed, by measuring micro-albuminuria and
arterial stiffness.
Other outcome measures
Other outcome parameters are values of body fat mea-
sured by bio-impedance compared to values of body fat
measured using DEXA scan, insulin sensitivity measured
by the whole body insulin sensitivity index compared
with insulin sensitivity calculated by HOMA-IR, HbA1c,
β-cell function calculated by HOMA-β%, oral disposition
index, insulin secretion calculated by the insulinogenic
index, physical fitness measured by validated fitness tests,
basal metabolic rate measured by calorimetry, and quality
of life measured by validated quality of life questionnaire.Limitations of the study
The major limitation of our study is in the open-label,
second part of the study. In this part, participants who
are still eligible for receiving metformin, i.e., who remain
insulin resistant and obese, may choose between taking the
drug or not. This will provide a bias in the second part of
the study, as participants motivated to lose weight are more
likely to choose metformin compared to non-motivated
participants. Possibly, this will cause an overestimation of
the efficacy of metformin during the second part off the
study. This will be taken into account when analysing the
results of the second part of the study. The open label con-
struction will not influence adverse reactions to the drug,
therefore making it possible to draw firm conclusions about
the 36-month safety and tolerability of metformin.
Discussion and trial status
This article provides the detailed study protocol of our
metformin study, including all objectives and outcome
measures, a description of the intervention and all study
procedures. After completion of the study, the gap in
knowledge of long-term effects of metformin on body
weight can be filled. Safety and tolerability of metformin
use up to 36 months will be investigated. Furthermore,
pharmacokinetics of metformin in obese children and
adolescents will be known.
Currently, the trial is ongoing and recruitment of par-
ticipants continues. To date, 60 participants have been
included, of whom 13 finished the first part of the trial.
Results on efficacy, safety, and tolerability of 18 months
of metformin treatment in obese children and adoles-
cents with insulin resistance are expected in summer
2015. First results of PK analysis are expected in autumn
2014. Long-term efficacy, safety, and tolerability results
are expected early 2017. These findings will be published
in international peer reviewed journals.
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